{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/NKTR/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-29T08:10:01.547Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9481,"canonical_name":"NEKTAR THERAPEUTICS","cik":"0000906709","uei":null,"lei":null,"duns":null,"ticker":"NKTR"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":17},"count":17,"timeline":[{"ts":"2026-06-30","kind":"sec.form144","reporter":"JONATHAN ZALEVSKY","title":"Officer","shares":5681,"usd_value":371481,"security_title":"Common","approx_sale_date":"2026-06-30","accession_number":"0001950047-26-006656","importance":40.074296118},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Zalevsky Jonathan","title":"Chief R&D Officer","shares":5681,"price_per_share":70,"usd_value":397670,"security_title":"Common Stock","importance":35.39767},{"ts":"2026-06-30","kind":"sec.filing","form_type":"144","title":"144 — Zalevsky Jonathan — 2026-06-30","url_slug":"/sec/cik-0001789857/144/0001950047-26-006656","accession_number":"0001950047-26-006656","importance":30},{"ts":"2026-06-17","kind":"sec.form144","reporter":"ROBIN HOWARD W","title":"Officer, Director","shares":10000,"usd_value":602700,"security_title":"Common","approx_sale_date":"2026-06-17","accession_number":"0001959173-26-004730","importance":40.12054},{"ts":"2026-06-17","kind":"sec.insider.s","reporter":"ROBIN HOWARD W","title":"President & CEO","shares":5500,"price_per_share":60.81,"usd_value":334455,"security_title":"Common Stock","importance":35.334455},{"ts":"2026-06-17","kind":"sec.insider.s","reporter":"ROBIN HOWARD W","title":"President & CEO","shares":4500,"price_per_share":61.65,"usd_value":277425,"security_title":"Common Stock","importance":35.277425},{"ts":"2026-06-16","kind":"sec.form144","reporter":"ROBIN HOWARD W","title":"Officer, Director","shares":10000,"usd_value":609600,"security_title":"Common","approx_sale_date":"2026-06-16","accession_number":"0001959173-26-004688","importance":40.12192},{"ts":"2026-06-16","kind":"sec.insider.s","reporter":"ROBIN HOWARD W","title":"President & CEO","shares":5303,"price_per_share":59.97,"usd_value":318021,"security_title":"Common Stock","importance":35.31802091},{"ts":"2026-06-16","kind":"sec.insider.s","reporter":"ROBIN HOWARD W","title":"President & CEO","shares":4697,"price_per_share":60.71,"usd_value":285155,"security_title":"Common Stock","importance":35.28515487},{"ts":"2026-06-15","kind":"sec.form144","reporter":"JONATHAN ZALEVSKY","title":"Officer","shares":5538,"usd_value":328846,"security_title":"Common","approx_sale_date":"2026-06-15","accession_number":"0001950047-26-006135","importance":40.065769288},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Zalevsky Jonathan","title":"Chief R&D Officer","shares":5538,"price_per_share":60.71,"usd_value":336212,"security_title":"Common Stock","importance":35.33621198},{"ts":"2026-06-05","kind":"sec.filing","form_type":"8-K","title":"8-K — NEKTAR THERAPEUTICS — 2026-06-05","url_slug":"/sec/cik-0000906709/8-k/0001213900-26-065845","accession_number":"0001213900-26-065845","importance":35},{"ts":"2026-05-19","kind":"sec.form144","reporter":"ROBIN HOWARD W","title":"Officer, Director","shares":444,"usd_value":29085,"security_title":"Common","approx_sale_date":"2026-05-19","accession_number":"0001959173-26-003768","importance":40.005816906},{"ts":"2026-05-19","kind":"sec.form144","reporter":"Zalevsky Jonathan","title":"Officer","shares":199,"usd_value":13036,"security_title":"Common","approx_sale_date":"2026-05-19","accession_number":"0001959173-26-003771","importance":40.002607126},{"ts":"2026-05-19","kind":"sec.insider.s","reporter":"ROBIN HOWARD W","title":"President & CEO","shares":444,"price_per_share":65.51,"usd_value":29086,"security_title":"Common Stock","importance":35.02908644},{"ts":"2026-05-19","kind":"sec.insider.s","reporter":"Zalevsky Jonathan","title":"Chief R&D Officer","shares":199,"price_per_share":65.51,"usd_value":13036,"security_title":"Common Stock","importance":35.01303649},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — NEKTAR THERAPEUTICS — 2026-05-15","url_slug":"/sec/cik-0000906709/schedule-13g-a/0000921895-26-001397","accession_number":"0000921895-26-001397","importance":30}]}